N-methyl-2-(2-nitrophenoxy)propanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methyl-2-(2-nitrophenoxy)propanamide
• 化学式: C10H12N2O4
• 分子量: 224.21
• InChiKey: UMTHTRNWDGTWTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• ESOPHAGEAL VALVE
  申请人：VYS RA Biomedical Limited

  公开号：EP2331017A1

  公开（公告）日：2011-06-15
• RECOMBINANT LECTINS, BINDING-SITE MODIFIED LECTINS AND USES THEREOF
  申请人：Smartcells, Inc.

  公开号：EP2598522A2

  公开（公告）日：2013-06-05
• [EN] ESOPHAGEAL VALVE<br/>[FR] CLAPET OESOPHAGIEN
  申请人：VYS RA BIOMEDICAL LTD

  公开号：WO2009153768A1

  公开（公告）日：2009-12-23

  An esophageal valve (1) comprising a polymeric valve body having an outer support region (2) at least three valve leaflets (3, 4, 5), and a main body region (6) extending between the support region (2) and the valve leaflets (3, 4, 5). The valve (1) has a normally closed configuration in which the valve (1) is closed, an antegrade open configuration in which the valve leaflets (3, 4, 5) are opened in response to an antegrade force to allow flow through the valve (1), and a retrograde open configuration in response to a retrograde force which is substantially larger than the antegrade force.
• [EN] RECOMBINANT LECTINS, BINDING-SITE MODIFIED LECTINS AND USES THEREOF<br/>[FR] LECTINES RECOMBINÉES, LECTINES À SITE DE LIAISON MODIFIÉ ET LEURS UTILISATIONS
  申请人：SMARTCELLS INC

  公开号：WO2012015691A2

  公开（公告）日：2012-02-02

  In one aspect, the disclosure provides cross-linked materials that include multivalent lectins with at least two binding sites for glucose, wherein the lectins include at least one affinity ligand which is capable of competing with glucose for binding with at least one of said binding sites and is covalently linked to a cysteine residue of the lectins; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with glucose for binding with the lectins at said binding sites and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between lectins and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of glucose. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label.